新福菌素注射液治疗低危型妊娠滋养细胞肿瘤的临床效果  

Clinical efficacy of actinomycin injection in the treatment of low-risk gestational trophoblastic neoplasia

作　　者：刘荣芳[1] 梅彤[1] 李冬晴 潘玫[1] 涂云霞[1] 华金仁 叶婷婷 刘成伟 陈丽 LIU Rongfang;MEI Tong;LI Dongqing;PAN Mei;TU Yunxia;HUA Jinren;YE Tingting;LIU Chengwei;CHEN Li(Jiangxi Maternal and Child Health Hospital,Nanchang 330006,China)

机构地区：[1]江西省妇幼保健院,南昌市330006

出　　处：《临床合理用药杂志》2024年第25期19-22,共4页Chinese Journal of Clinical Rational Drug Use

基　　金：江西省卫生健康委科技计划项目(202130842)。

摘　　要：目的 观察新福菌素注射液治疗低危型妊娠滋养细胞肿瘤(LRGTN)的临床效果。方法 选取2020年1月—2022年6月江西省妇幼保健院收治的LRGTN患者60例,采用随机数字表法分为新福菌素组与常规组,每组30例。常规组接受“8日疗法”治疗,新福菌素组予新福菌素注射液治疗。比较2组近期疗效、达到完全缓解所用时间,治疗前后血清β-人绒毛膜促性腺激素(β-HCG)水平及不良反应。结果 新福菌素组与常规组治疗总缓解率(96.67%vs.90.00%)比较差异无统计学意义(χ^(2)=0.268,P=0.605);新福菌素组完全缓解时间为(73.10±13.87)d,短于常规组的(88.93±16.47)d(t=4.027,P<0.001);治疗1个疗程后,2组β-HCG水平较治疗前降低,且新福菌素组低于常规组(P均<0.01);新福菌素组与常规组1~2级不良反应发生率中肝损伤(6.67%vs.46.67%)、口腔溃疡(46.67%vs.73.33%)以及3~4级不良反应发生率中骨髓抑制(6.67%vs.26.67%)组间比较差异有统计学意义(P<0.05或P<0.01)。结论 新福菌素相比常规方案治疗LRGTN的临床效果相当,但新福菌素组达到完全缓解所用时间更短,且部分不良反应发生风险更低。Objective To observe the clinical efficacy of actinomycin injection in the treatment of low-risk gestational trophoblastic neoplasia(LRGTN).Methods Sixty patients with LRGTN admitted to Jiangxi Maternal and Child Health Hospital from January 2020 to June 2022 were selected and randomly divided into an actinomycin group and a conventional group,with 30 patients in each group.The conventional group received the "eight-day regimen" treatment,while the actinomycin group was treated with actinomycin injection.The short-term efficacy,time to complete remission,serum β-human chorionic gonadotropin(β-HCG) levels before and after treatment,and adverse reactions were compared between the two groups.Results There was no statistically significant difference in the overall effective rate between the actinomycin group and the conventional group(96.67% vs.90.00%,χ^(2)=0.268,P=0.605).The time to complete remission was shorter in the actinomycin group(73.10±13.87 days) compared to the conventional group(88.93±16.47 days)(t=4.027,P<0.001).After one course of treatment,β-HCG levels in both groups decreased compared to before treatment,with the actinomycin group showing lower levels than the conventional group(P<0.01).The incidence of grade 1-2 adverse reactions,including liver damage(6.67% vs.46.67%) and oral ulcers(46.67% vs.73.33%),as well as grade 3-4 adverse reactions,such as myelosuppression(6.67% vs.26.67%),showed statistically significant differences between the two groups(P<0.05 or P<0.01).Conclusion The clinical efficacy of actinomycin in the treatment of LRGTN is comparable to the conventional regimen,but the time to complete remission is shorter in the actinomycin group,and the risk of certain adverse reactions is lower.

关 键 词：妊娠滋养细胞肿瘤 低危型 新福菌素 甲氨蝶呤 近期疗效 

分 类 号：R737.33[医药卫生—肿瘤]